Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis

Clinical Science

Volumn 116, Issue 1, 2009, Pages 71-79

  Yang, Ying Ying ^a,b   Huang, Yi Tsau ^b   Lee, Kuei Chuan ^b   Lee, Fa Yauh ^a,b   Lee, Tzung Yan ^c   Hou, Ming Chih ^a,b   Lin, Han Chieh ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Antioxidant; Cirrhosis; Fibrosis; Intrahepatic resistance; Portal venous pressure; Ursodeoxycholic acid (UCDA)

Indexed keywords

COLLAGEN; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NITRITE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THROMBOXANE A2; THROMBOXANE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA1; URSODEOXYCHOLIC ACID; ANTIOXIDANT; COLLAGEN TYPE 3; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE III N TERMINAL PEPTIDE; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BILIARY CIRRHOSIS; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; ENZYME SYNTHESIS; GENE EXPRESSION; HEMODYNAMICS; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER FUNCTION; LIVER HISTOLOGY; LIVER PERFUSION; MALE; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; SPLANCHNIC BLOOD FLOW; ANIMAL; BIOSYNTHESIS; DRUG ADMINISTRATION; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LIVER; LIVER CIRCULATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; SPRAGUE DAWLEY RAT; VASCULAR RESISTANCE;

ANIMALS; ANTIOXIDANTS; COLLAGEN TYPE III; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; HEMODYNAMICS; HYPERTENSION, PORTAL; LIPID PEROXIDATION; LIVER; LIVER CIRCULATION; LIVER CIRRHOSIS, BILIARY; MALE; PEPTIDE FRAGMENTS; PORTAL PRESSURE; PROCOLLAGEN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; URSODEOXYCHOLIC ACID; VASCULAR RESISTANCE;

EID: 60549102503     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080075     Document Type: Article

References (52)

1. Sikuler, E., Kravetz, D. and Groszmann, R. J. (1985) Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am. J. Physiol. 248, G618-G625
2. Graupera, M., Garcća-Pagán, J. C., Abraldes, J. G. et al. (2003) Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 37, 172-181
3. Rockey, D. C. (2003) Vascular mediators in the injured liver. Hepatology 37, 4-12
4. Natarajan, S. K., Thomas, S., Ramamoorthy, P. et al. (2006) Oxidative stress in the development of liver cirrhosis: a comparison of two different experimental models. Hepatology 21, 947-957
5. Bosch, J., Abraldes, J. G. and Groszmann, R. J. (2003) Current management of portal hypertension. J. Hepatol. 38, S54-S68
6. Jain, S. K., Pemberton, P. W., Smith, A. et al. (2002) Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J. Hepatol. 36, 805-811
7. Muriel, P. (1997) Peroxidation of lipids and liver damage. In Oxidants, Antioxidants, and Free Radicals (Baskia, S. I. and Salem, H. eds), pp. 237-257, Taylor & Francis, Washington
8. Reiter, R. J., Acuno-Castroviejo, D., Tan, D. and Burkhart, S. (2001) Free radical-mediated molecular damage. Ann. N.Y. Acad. Sci. 939, 200-215
9. Svegliati-Baroni, G., Saccomanno, S., van Goor, H., Jansen, P., Benedetti, A. and Moshage, H. (2001) Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 21, 1-12
10. Bomzon, A. and Ljubuncic, P. (2001) Oxidative stress and vascular smooth muscle cell function in liver disease. Pharmacol. Ther. 89, 295-308
11. Wong, F., Bernardi, M., Balk, R. et al. (2005) Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 54, 718-725
12. 2 activity, and hepatic toxicity in rats with cirrhosis. J. Hepatol. 33, 376-381
13. Szabo, G., Romics, Jr, L. and Frendl, G. (2002) Liver in sepsis and systemic inflammatory response syndrome. Clin. Liver Dis. 6, 1045-1066
14. Sokol, R. J., Devereaux, M., Khandwala, R. and O'Brien, K. (1993) Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatology 17, 869-881
15. Heuman, D. M. (1993) Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 104, 1865-1870
16. Simko, V. and Michael, S. (1994) Effect of ursodeoxycholic acid on in vivo and in vitro toxic liver injury in rats. Aliment. Pharmacol. Ther. 8, 315-322
17. Heuman, D. M. and Bajaj, R. (1994) Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 106, 1333-1341
18. de Caestecker, J. S., Jazrawi, R. P., Petroni, M. L. and Northfield, T. C. (1991) Ursodeoxycholic acid in chronic liver disease. Gut 32, 1061-1065
19. Luketic, V. A. and Sanyal, A. J. (1994) The current status of urodexycholate in the treatment of chronic cholestatic liver disease. Gastroenterologist 2, 74-79
20. Wong, F., Bomzon, A., Allard, J., Liu, P. and Blendis, L. (1999) Effects of ursodeoxycholic acid on systemic renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites. Clin. Sci. 96, 467-474
21. Tasci, I., Mas, M. R., Vural, S. A. et al. (2006) Rat liver fibrosis regresses better with PEGylated interferon α2b and ursodeoxycholic acid treatments than spontaneously recovery. Liver Int. 26, 261-268
22. Lin, H. C., Huang, Y. T., Wu, H. L. et al. (1999) Effect of sustained release lanreotide on hemodynamics in rats with portal vein stenosis. J. Hepatol. 31, 482-488
23. 1 cannabinoid receptor antagonism on liver of rats with biliary cirrhosis. Clin. Sci. 112, 561-572
24. Ma, J., Nakajima, T., Iida, H. et al. (2003) Inhibitory effect of ursodeoxycholic acid on the induction of nitric oxide synthase in vascular smooth muscle cells. Eur. J. Pharmacol. 464, 79-86
25. Chang, T. T., Lin, H. C., Lee, S. D. et al. (1989) Clinical significance of serum type-III procollagen aminopropeptide in hepatitis B virus-related liver diseases. Scand. J. Gastroenterol. 24, 533-538
26. Serviddio, G., Pereda, J., Pallardo, F. V. et al. (2004) Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 39, 711-720
27. Lukivskaya, O., Zavodnik, L., Knas, M. and Buko, V. (2006) Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Adv. Med. Sci. 51, 54-59
28. Rodriguez-Ortigosa, C.M., Cincu, R. N., Sanz, S., Ruiz, F., Quiroga, J. and Prieto, J. (2002) Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats. Gut 50, 701-706
29. Kawamura, K., Kobayashi, Y., Kageyama, F. et al. (2000) Enhanced hepatic lipid peroxidation in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 95, 3596-3601
30. Krähenbühl, S., Talos, C., Lauterburg, B. H. and Reichen, J. (1995) Reduced oxidative capacity in liver mitochondria from bile duct ligated rats. Hepatology 22, 607-612
31. Hierholzer, C., Harbrecht, B., Menezes, J. M. et al. (1998) Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrage shock. J. Exp. Med. 187, 917-928
32. Bohlinger, I., Leist, M., Barsig, J., Uhlig, S., Tiegs, G. and Wendel, A. (1995) Interleukin-1 and nitric oxide protect tumor necrosis factor α-induced liver injury through distinct pathways. Hepatology 22, 1829-1837
33. 4-induced acute liver injury of mice. Free Radical Biol. Med. 29, 870-880
34. Morio, L. A., Chiu, H., Sprowles, K. A. et al. (2001) Distinct roles of tumor necrosis factor-α and nitric oxide in acute liver injury induced by carbon tetrachloride in mice. Toxicol. Appl. Pharmacol. 172, 44-51
35. Vos, T. A., Van Goor, H., Tuyt, L. et al. (1999) Content of inducible nitric oxide synthase in endotoxemia rat hepatocytes in dependent on the cellular glutathione status. Hepatology 29, 421-426
36. Nadler, E. P., Dickinson, E. C., Beer-Stolz, D. et al. (2001) Scavenging nitric oxide reduces hepatocellular injury after endotoxin challenge. Am. J. Physiol. Gastrointest. Liver Physiol. 281, G173-G181
37. Caglikulekci, M., Pata, C., Apa, D. D. et al. (2004) The effect of N-acetylcysteine (NAC) in liver and renal tissue inducible nitric oxide synthase (iNOS) and tissue lipid peroxidation in obstructive jaundice stimulated by lipopolysaccharide (LPS). Pharmacol. Res. 49, 227-238
38. Hattori, Y., Murakami, Y., Hattori, S., Kuroda, H., Kasai, K. and Shimoda, S. (1996) Ursodeoxycholic acid inhibits the induction of nitric oxide synthase. Eur. J. Pharmacol. 300, 147-150
39. Wei, C. L., Hon, W. M., Lee, K. H. and Khoo, H. E. (2005) Chronic administration of aminoguanidine reduces vascular nitric oxide production and attenuates liver damages in bile duct ligated rats. Liver Int. 25, 647-656
40. Fiorotto, R., Spirli, C., Fabris, L., Cadamuro, M., Okolicsanyi, L. and Strazzabosco, M. (2007) Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology 133, 1603-1613
41. Sokol, R. J., Winklhofer-Roob, B. M., Devereaux, M. W. and McKim, Jr, J. M. (1995) Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology 109, 1249-1256
42. Paumgartner, G. and Beuers, U. (2002) Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36, 525-531
43. Napoli, J., Prentice, D., Niinami, C., Bishop, G. A., Desmond, P. and McCaughan, G. W. (1997) Sequential increases in the intrahepatic expression of epidermal growth factor-β in bile duct ligation rat model of cirrhosis. Hepatology 26, 624-633
44. Lamireau, T., Le Bail, B., Boussarie, L. et al. (1999) Expression of collagen type I and IV, osteonectin and transforming growth factor-β1 (TGF-β1) in biliary atresia and paucity of intrahepatic bile ducts in infancy. J. Hepatol. 31, 248-255
45. Neuman, M., Angulo, P., Malkiewicz, I. et al. (2002) Tumor necrosis factor α and transforming growth factor-β reflect severity of liver damage in primary biliary cirrhosis. J. Gastroenterol. Hepatol. 17, 196-202
46. Sola, S., Ma, X., Castro, R. E., Kren, B. T., Steer, C. J. and Rodrigues, C. M. (2003) Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor β1-induced apoptosis of rat hepatocytes. J. Biol. Chem. 278, 48831-48838
47. Augulo, P., Dickson, E. R., Therneau, T. et al. (1999) Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J. Hepatol. 30, 830-835
48. Rost, D., Rudolph, G., Kloeters-Plachky, P. and Stiehl, A. (2004) Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 40, 693-598
49. Okolicsanyi, L., Groppo, M., Floreani, A. et al. (2003) Treatment of primary sclerosing cholangitis with low dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dis. Liver Dis. 35, 325-331
50. Cullen, S. N., Rust, C., Fleming, K., Edwards, C., Beuers, U. and Chapman, R. W. (2008) High dose ursodexycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J. Hepatol. 48, 792-800
51. Schiedermaier, P., Hansen, S., Asdonk, D., Brensing, K. A. and Sauerbuch, T. (2000) Effects of ursodeoxycholic acid on splanchnic and systemic hemodynamics. Digestion 61, 107-121
52. Gonzales-Abraldes, J., Garcia-Pagan, J. C. and Bosch, J. (2002) Nitric oxide and portal hypertension. Metab. Brain Dis. 17, 311-324